SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs8069645

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Effect of Polymorphisms in CD36 and STAT3 Genes on Different Dietary Interventions Among Patients With Coronary Artery Disease: a Randomized Clinical Trial With a Nutrigenetic Approach

Background: Cardiovascular diseases are the major health problem worldwide and the understanding of genetic contributions on the development of cardiovascular diseases is increasing significantly. The CD36 is a protein associated with uptake of oxidized forms of LDL and the single nucleotide polymorphism (SNP) rs1761667 A/G in the CD36 gene is correlated with increased consumption of total fat. The transcription factor STAT3 is released during the inflammatory acute phase response and the SNP rs8069645 G/A in the STAT3 gene is associated with abdominal obesity and higher intake of saturated fat. Studies have been shown the benefits of the Mediterranean diet in secondary prevention of cardiovascular disease and these dietary patterns have been often studied with nutrigenetic approach; these studies, however, are often limited to European populations, making it difficult to generalize to different populations. Hypothesis: Different dietary approaches may similarly influence in modifying metabolic, inflammatory and anthropometric profile, especially among patients with coronary arterial disease (CAD). The genetic interaction with environmental factors such as the nutrient intake, and the prescription of a different diet according to individual genotype, could influence the development and/or the treatment of cardiovascular diseases. Objective: To evaluate the effect of three dietary approaches on metabolic, inflammatory and anthropometric profile in patients with CAD and possible interactions with polymorphisms in CD36 and STAT3 genes.

NCT02202265 Coronary Artery Disease Dietary Supplement: Olive oil Dietary Supplement: Nuts Dietary Supplement: Control diet
MeSH: Coronary Artery Disease Myocardial Ischemia Coronary Disease
HPO: Coronary artery atherosclerosis

The transcription factor STAT3 is released during the inflammatory acute phase response and the SNP rs8069645 G/A in the STAT3 gene is associated with abdominal obesity and higher intake of saturated fat.

Primary Outcomes

Description: LDL-cholesterol, in mg/dL

Measure: LDL

Time: twelve weeks

Secondary Outcomes

Description: total cholesterol (TC), in mg/dL)

Measure: TC

Time: twelve weeks

Description: non-HDL-cholesterol, in mg/dL

Measure: NHDL

Time: twelve weeks

Description: HDL-cholesterol, in mg/dL

Measure: HDL

Time: twelve weeks

Description: serum triglyceride, in mg/dL

Measure: TG

Time: twelve weeks

Description: glycated hemoglobin (HbA1C), in %

Measure: HbA1C

Time: twelve weeks

Description: fasting glucose, in mg/dL

Measure: FG

Time: twelve weeks

Description: serum insulin, in UI/mL

Measure: Insulin

Time: twelve weeks

Description: Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), calculated according to fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5

Measure: HOMA-IR

Time: twelve weeks

Description: CRP-us, in mg/dL; IL-6, in mg/dL; IL-10, in mg/dL

Measure: inflammatory profile

Time: twelve weeks

Description: body weight, in kg;

Measure: BW

Time: twelve weeks

Description: body mass index (BMI), in kg/m2, calculated according to weight (kg)/height*height (m)

Measure: BMI

Time: twelve weeks

Description: waist circumference, in cm

Measure: WC

Time: twelve weeks

Description: plasma fatty acids, in %

Measure: PFA

Time: twelve weeks


HPO Nodes


Coronary artery atherosclerosis
Genes 48
LMNA LDLRAP1 LDLR ACTA2 CYP7A1 FBN1 APOE APOB ESR1 MAT2A ABCA1 KCNJ5 ABCG8 MYH11 ZNF687 TGFB2 LMNA LMNA ELN LMNA LIPC PPARG LMNA FOXE3 SERPIND1 SMAD4 TGFBR2 SMPD1 MFAP5 ABCA1 APOB LMNA LOX SMAD3 MYH11 MYH11 LOX LMNA PCSK9 ACTA2 ABCG8 ZMPSTE24 TGFB3 PRKG1 TGFBR1 MYLK CEP19 ABCG5